Researchers have developed analogues of vancomycin with three independent and synergistic mechanisms of action. Developing antibiotics that overcome resistance often focuses on improving a drug's fit with its binding pocket, but much like in the development of antitumor drugs, bacteria can evolve resistance to such second-generation inhibitors as well.